Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration

Approval of B-cell-depleting therapies signifies an important advance in the treatment of multiple sclerosis (MS). However, it is unclear whether the administration route of anti-CD20 monoclonal antibodies (mAbs) alters tissue distribution patterns and subsequent downstream effects. This study aimed...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Julia Baguña Torres, Jay Roodselaar, Megan Sealey, Marina Ziehn, Marc Bigaud, Rainer Kneuer, David Leppert, Gisbert Weckbecker, Bart Cornelissen, Daniel C. Anthony
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2022-07-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	ofatumumab ocrelizumab subcutaneous intravenous multiple sclerosis distribution
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.814064/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!